Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of RegenxBio's RGX-111?
RGX-111 is a gene therapy commercialized by RegenxBio, with a leading Phase II program in Mucopolysaccharidosis I (MPS I) (Hurler...
Data Insights
Risk adjusted net present value: What is the current valuation of RegenxBio's RGX-111?
RGX-111 is a gene therapy commercialized by RegenxBio, with a leading Phase II program in Mucopolysaccharidosis I (MPS I) (Hurler...